Lactobacillus Paracasei Postbiotic Eye Drops for Conjunctivitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conjunctivitis, particularly Vernal keratoconjunctivitis (VKC), are limited in effectiveness and often come with adverse side effects, and there is a need for alternative therapies that do not disrupt the eye microbiota composition.
Innovation Solution
A fermented product of Lactobacillus casei or paracasei species, specifically the supernatant of Lactobacillus paracasei CNCM I-1390, is used to create an eyedrop formulation that acts as a postbiotic, providing anti-inflammatory and immunomodulatory effects without introducing live bacteria or microbial-associated molecular patterns, thereby protecting the eye mucosa from infections and allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroids or cyclosporine are used to treat severe VKC cases, then inflammation is suppressed, but adverse side effects occur (increased intraocular pressure, cataract formation, glaucoma)
Solution Approach 1:
The patent extracts the beneficial anti-inflammatory properties of Lactobacillus paracasei by using its fermentation supernatant (postbiotic) instead of the whole organism. This allows obtaining immunomodulatory effects while eliminating the need for harmful immunosuppressive drugs like steroids and cyclosporine, thus resolving the contradiction between efficacy and side effects
Solution Approach 2:
The patent changes the therapeutic approach from using pharmacological immunosuppressants to using a biologically derived postbiotic product. By transforming the treatment parameter from chemical immunosuppression to microbial fermentation product, the therapy maintains anti-inflammatory efficacy while eliminating adverse side effects associated with traditional medications
2Reliability
If probiotics are administered to treat conjunctivitis, then immune modulation is achieved, but the eye microbiota composition may be disrupted
Solution Approach 1:
The patent extracts the active immunomodulatory components (fermentation products, metabolites, exopolysaccharides) from the Lactobacillus paracasei organism and uses only the supernatant. This allows delivering therapeutic benefits while completely avoiding introduction of live bacteria that could disrupt the eye microbiota, thus resolving the contradiction between immunomodulation and microbiota stability
Solution Approach 2:
The patent uses the fermentation supernatant as an intermediary substance that carries the immunomodulatory effects without requiring live bacterial presence. The postbiotic product acts as a mediator that transfers the beneficial effects of Lactobacillus paracasei while leaving the microbiota composition unchanged, resolving the contradiction between achieving therapeutic effect and maintaining microbiota stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The postbiotic formulation effectively reduces inflammation, promotes epithelial barrier formation, and modulates the immune response to protect the eye from pathogens and allergic reactions, offering a safer and more effective treatment for conjunctivitis and VKC without altering the eye microbiota.
Implementation Method 1
A fermented product of Lactobacillus casei or paracasei species, preferably for use in the treatment of eye inflammation syndromes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention refers to a composition comprising a fermented product of Lactobacillus casei or paracasei species, preferably for use in the treatment of eye inflammation syndromes and to a method for obtaining the same.